Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held by Stellus Capital Investment Corp on July 22, 2019. The meeting was originally scheduled for June 27, 2019, but was postponed by the Board of Directors to solicit additional votes. As of the record date (April 5, 2019), 18,703,810.65 shares of common stock were eligible to be voted.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Voting Results
Of the shares eligible to be voted, 9,914,254 were voted in person or by proxy. Two proposals were submitted and approved:
- Proposal 1: Election of Directors
- Dean D'Angelo: Elected for a three-year term. Votes For: 8,291,412; Votes Withheld: 1,622,842.
- William C. Repko: Elected for a three-year term. Votes For: 8,193,242; Votes Withheld: 1,721,012.
- Proposal 2: Issuance of Shares Below Net Asset Value (NAV)
- Shareholders approved the authorization for the Company to sell or issue up to 25% of its outstanding common stock at an offering price below the then-current NAV per share, subject to Board approval.
- Voting Results: Votes For: 8,375,490; Votes Against: 1,305,018; Abstentions: 233,739.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly details the procedural outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the impact of the approved "Below NAV" issuance authority on future capital raising strategies and potential dilution.
- Confirm the tenure and background of the newly elected directors, Dean D'Angelo and William C. Repko.
- Note that the Annual Meeting was postponed from June to July to solicit additional votes, indicating potential initial uncertainty regarding proposal passage.
- Review the Company's proxy statement dated April 19, 2019, for detailed descriptions of the proposals and director biographies.